Open AccessBrief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials
Author(s) -
Chloe Orkin,
F. Ajana,
Cissy Kityo,
Ellen Koenig,
Eva Natukunda,
Bhumi Gandhi-Patel,
Hui Wang,
Yapei Liu,
Xuelian Wei,
Kirsten White,
Tariro Makadzange,
Cheryl Pikora,
Ian R. McNicholl,
Sean E Collins,
Diana M. Brainard,
Susan K. Chuck
Publication year - 2021
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002789
Subject(s) - emtricitabine , medicine , tenofovir alafenamide , regimen , adverse effect , population , human immunodeficiency virus (hiv) , viral load , immunology , antiretroviral therapy , environmental health
We characterized the efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in a broad population of pediatric/adolescent/adult/elderly females living with HIV (FWH).